AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN), a developer of targeted molecular therapies for cancer, today announced that the company will present the results from its recently completed Phase 3 trial of ADVEXIN in recurrent head and neck cancer at the American Association for Cancer Research (AACR) Centennial Conference on Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine. The conference will be held July 20-23, 2008 at the Hyatt Regency Monterey in Monterey, CA.
